Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Prime Capital Investment Advisors LLC decreased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 65.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,464 shares of the biotechnology company's stock after selling 6,476 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Blueprint Medicines were worth $320,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Triad Wealth Partners LLC acquired a new stake in shares of Blueprint Medicines during the 2nd quarter valued at $27,000. Covestor Ltd grew its stake in Blueprint Medicines by 9,700.0% in the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 291 shares in the last quarter. Natixis acquired a new position in Blueprint Medicines in the 1st quarter worth about $73,000. CWM LLC raised its stake in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company's stock worth $119,000 after purchasing an additional 590 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in shares of Blueprint Medicines by 13.3% during the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $120,000 after buying an additional 131 shares during the last quarter.

Insider Transactions at Blueprint Medicines

In other news, insider Fouad Namouni sold 3,633 shares of the company's stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This represents a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 4.21% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Guggenheim raised their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price objective for the company. StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, November 8th. Robert W. Baird boosted their price target on Blueprint Medicines from $112.00 to $127.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. Finally, HC Wainwright reiterated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $122.11.

Blueprint Medicines Stock Performance

BPMC traded down $6.96 on Friday, hitting $88.69. 1,001,074 shares of the stock traded hands, compared to its average volume of 712,987. The business has a fifty day moving average price of $89.59 and a two-hundred day moving average price of $98.94. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $5.63 billion, a PE ratio of -42.03 and a beta of 0.59. Blueprint Medicines Co. has a 52 week low of $62.56 and a 52 week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million for the quarter, compared to analysts' expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Blueprint Medicines's quarterly revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the business posted ($2.20) earnings per share. On average, research analysts predict that Blueprint Medicines Co. will post -3.61 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.